Compugen Inks Peptide Collaboration with Merck | GenomeWeb
NEW YORK (GenomeWeb News) – Compugen said today it will collaborate with Merck to predict and validate peptides that are likely to activate G-protein coupled receptors that Merck could use in its drug development programs.
 
The agreement, which Compugen said is its first such peptide collaboration, includes an option that would grant Merck exclusive worldwide licenses to develop and market these peptides.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.